product summary
Loading...
company name :
R&D Systems
product type :
antibody
product name :
Human TRAILR4/TNFRSF10D Antibody
catalog :
MAB633
quantity :
500 ug (also 25 ug)
price :
579 USD
clonality :
monoclonal
host :
mouse
conjugate :
nonconjugated
clone name :
104918
reactivity :
human
application :
ELISA, neutralization, flow cytometry, blocking or activating experiments
more info or order :
R&D Systems product webpage
citations: 21
Published Application/Species/Sample/DilutionReference
  • blocking or activating experiments; human; fig 3
Suzuki Karasaki Y, Fujiwara K, Saito K, Suzuki Karasaki M, Ochiai T, Soma M. Distinct effects of TRAIL on the mitochondrial network in human cancer cells and normal cells: role of plasma membrane depolarization. Oncotarget. 2015;6:21572-88 pubmed
  • flow cytometry; human
Moniri M, Sun X, Rayat J, Dai D, Ao Z, He Z, et al. TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells. Cancer Gene Ther. 2012;19:652-8 pubmed publisher
  • flow cytometry; human; 5 ug/ml
Moriwaki K, Shinzaki S, Miyoshi E. GDP-mannose-4,6-dehydratase (GMDS) deficiency renders colon cancer cells resistant to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor- and CD95-mediated apoptosis by inhibiting complex II formation. J Biol Chem. 2011;286:43123-33 pubmed publisher
  • flow cytometry; human
Zauli G, Rimondi E, Celeghini C, Milani D, Secchiero P. Dexamethasone counteracts the anti-osteoclastic, but not the anti-leukemic, activity of TNF-related apoptosis inducing ligand (TRAIL). J Cell Physiol. 2010;222:357-64 pubmed publisher
  • flow cytometry; human
Stary G, Klein I, Kohlhofer S, Koszik F, Scherzer T, Müllauer L, et al. Plasmacytoid dendritic cells express TRAIL and induce CD4+ T-cell apoptosis in HIV-1 viremic patients. Blood. 2009;114:3854-63 pubmed publisher
  • flow cytometry; human
Secchiero P, Melloni E, Corallini F, Beltrami A, Alviano F, Milani D, et al. Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells. Stem Cells. 2008;26:2955-63 pubmed publisher
  • flow cytometry; human
Toscano F, Fajoui Z, Gay F, Lalaoui N, Parmentier B, Chayvialle J, et al. P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells. Oncogene. 2008;27:4161-71 pubmed publisher
  • flow cytometry; human
Weinmann L, Wischhusen J, Demma M, Naumann U, Roth P, Dasmahapatra B, et al. A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ. 2008;15:718-29 pubmed publisher
  • flow cytometry; human
Barbarotto E, Corallini F, Rimondi E, Fadda R, Mischiati C, Grill V, et al. Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cells. J Cell Biochem. 2008;104:595-605 pubmed
Ben Khaled N, Hammer K, Ye L, Alnatsha A, Widholz S, Piseddu I, et al. TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation Status. Cancers (Basel). 2022;14: pubmed publisher
Krishna Moorthy N, Seifert O, Eisler S, Weirich S, Kontermann R, Rehm M, et al. Low-Level Endothelial TRAIL-Receptor Expression Obstructs the CNS-Delivery of Angiopep-2 Functionalised TRAIL-Receptor Agonists for the Treatment of Glioblastoma. Molecules. 2021;26: pubmed publisher
Yoo J, Bae S, Seo J, Jeon I, Vadevoo S, Kim S, et al. Designed ferritin nanocages displaying trimeric TRAIL and tumor-targeting peptides confer superior anti-tumor efficacy. Sci Rep. 2020;10:19997 pubmed publisher
Danish L, Imig D, Allgöwer F, Scheurich P, Pollak N. Bcl-2-mediated control of TRAIL-induced apoptotic response in the non-small lung cancer cell line NCI-H460 is effective at late caspase processing steps. PLoS ONE. 2018;13:e0198203 pubmed publisher
Neumann S, Hasenauer J, Pollak N, Scheurich P. Dominant negative effects of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 4 on TRAIL receptor 1 signaling by formation of heteromeric complexes. J Biol Chem. 2014;289:16576-87 pubmed publisher
Tang X, Lu J, Tu H, Huang K, Fu R, Cao G, et al. TRAIL-engineered bone marrow-derived mesenchymal stem cells: TRAIL expression and cytotoxic effects on C6 glioma cells. Anticancer Res. 2014;34:729-34 pubmed
Shankar S, Chen Q, Ganapathy S, Singh K, Srivastava R. Diallyl trisulfide increases the effectiveness of TRAIL and inhibits prostate cancer growth in an orthotopic model: molecular mechanisms. Mol Cancer Ther. 2008;7:2328-38 pubmed publisher
Locklin R, Federici E, Espina B, Hulley P, Russell R, Edwards C. Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis. Mol Cancer Ther. 2007;6:3219-28 pubmed
Salehi E, Vodjgani M, Massoud A, Keyhani A, Rajab A, Shafaghi B, et al. Increased expression of TRAIL and its receptors on peripheral T-cells in type 1 diabetic patients. Iran J Immunol. 2007;4:197-205 pubmed
Braun F, Fecker L, Schwarz C, Walden P, Assaf C, Dürkop H, et al. Blockade of death receptor-mediated pathways early in the signaling cascade coincides with distinct apoptosis resistance in cutaneous T-cell lymphoma cells. J Invest Dermatol. 2007;127:2425-37 pubmed
Hesry V, Piquet Pellorce C, Travert M, Donaghy L, Jégou B, Patard J, et al. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players. Prostate. 2006;66:987-95 pubmed
Singh T, Shankar S, Srivastava R. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma. Oncogene. 2005;24:4609-23 pubmed
product information
master code :
MAB633
SKU :
MAB633
product name :
Human TRAILR4/TNFRSF10D Antibody
unit size :
500 ug (also 25 ug)
description :
The Human TRAILR4/TNFRSF10D Antibody from R&D Systems is a mouse monoclonal antibody to TRAILR4/TNFRSF10D/DcR2. This antibody reacts with human,rat. The Human TRAILR4/TNFRSF10D Antibody has been validated for the following applications: Flow Cytometry,Neutralization,ELISA Capture (Matched Antibody Pair),CyTOF-ready.
target :
TRAILR4/TNFRSF10D
category :
Primary Antibodies
buffer :
Lyophilized from a 0.2 ╡m filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 ╡m filtered solution in PBS.
clonality :
Monoclonal
clone :
104918
conjugate :
Unconjugated
host :
Mouse
immunogen :
Mouse myeloma cell line NS0-derived recombinant human TRAIL R4/TNFRSF10D, Ala56-His211, Accession # Q9UBN6
isotype :
IgG1
purity :
Protein A or G purified from ascites
species :
Human,Rat
specificity :
Detects human TRAIL R4/TNFRSF10D in ELISAs and Western blots. In sandwich immunoassays, less than 5% cross-reactivity with recombinant human (rh) TRAIL R1, rhTRAIL R2, TRAIL R3, rhTRAIL, rhTNF-alpha , and rhTNF┐▀ is observed.
gene symbol :
TNFRSF10D
endotoxin note :
<0.10 EU per 1 ╡g of the antibody by the LAL method.
top caption :
TRAIL R4/TNFRSF10D Inhibition of TRAIL/TNFSF10-induced Cytotoxicity and Neutralization by Human TRAIL R4/TNFRSF10D Antibody.
accessionNumbers :
Q9UBN6
applications :
Flow Cytometry,Neutralization,ELISA Capture (Matched Antibody Pair),CyTOF-ready
USD :
579 USD
alt names :
CD264, CD264 antigen, DcR2, DCR2decoy with truncated death domain, Decoy receptor 2, TNF receptor-related receptor for TRAIL, TNF-related apoptosis-inducing ligand receptor 4, TNFRSF10D, TRAIL R4, TRAIL-R4, TRAILR4TRAIL receptor 4, TRUNDDTRAIL receptor with a truncated death domain, tumor necrosis factor receptor superfamily member 10D, tumor necrosis factor receptor superfamily, member 10d, decoy with truncateddeath domain
storage :
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 ░C as supplied. 1 month, 2 to 8 ░C under sterile conditions after reconstitution. 6 months, -20 to -70 ░C under sterile conditions after reconstitution.
more info or order :
R&D Systems product webpage
company information
R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com
800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.